Hematological toxicities in antibody–drug conjugates related with breast cancer: a pharmacovigilance study using FDA adverse event reporting system database

The study indicated that hematological toxicities caused by ADCs preferentially emerge early and may have catastrophic consequences. Early detection and management of these hematological toxicities associated with ADC is essential.